[1]蔡亚红,唐方明.蒽环类药物的心脏毒性预防措施研究进展[J].新乡医学院学报,2018,35(3):244-247.[doi:10.7683/xxyxyxb.2018.03.021]
 N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(3):244-247.[doi:10.7683/xxyxyxb.2018.03.021]
点击复制

蒽环类药物的心脏毒性预防措施研究进展
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年3
页码:
244-247
栏目:
综述
出版日期:
2018-03-05

文章信息/Info

Title:
N/A
作者:
蔡亚红唐方明
(1.广东医科大学研究生学院,广东 湛江 524000;2.广东省农垦中心医院心血管内科,广东 湛江 524000)
Author(s):
N/A
N/A
关键词:
蒽环类药物心脏毒性肿瘤心脏病学预防
Keywords:
N/A
分类号:
R969.4
DOI:
10.7683/xxyxyxb.2018.03.021
文献标志码:
A
摘要:
蒽环类药物已普遍应用于实体瘤和血液系统肿瘤的治疗,并取得了显著疗效,但其临床应用的安全性,特别是心脏毒性越来越受到重视。目前,唯一获批的预防蒽环类所致心脏毒性的药物为右雷佐生,但其临床使用仍存在一定限制。因此,探究能预防蒽环类药物心脏毒性的药物是肿瘤心脏病学医生亟待解决的问题,对肿瘤患者的生存率及生活质量有重要意义。本文将近年研究认为极具应用前景的预防蒽环类药物心脏毒性的方法进行综述。
Abstract:
N/A

参考文献/References:

[1] CAMERON A C,TOUYZ R M,LANG N N,et al.Vascular complications of cancer chemot herapy[J].Can J Cardiol,2016,32(7):852-862.
[2] BELLINGER A M,ARTEAGA C L,FORCE T,et al.Cardio-oncology:how new targeted cancer therapies and precision medicine can inform cardiovascular discovery[J].Circulation,2015,132(23):2248-2258.
[3] 中国临床肿瘤学会,中华医学会血液学分会.蒽环类药物心脏毒性防治指南[J].临床肿瘤学杂志,2013,18(10):925-934.
[4] PIEPOLI M F,HOES A W,AGEWALL S,et al.2016 European guidelines on cardiovascular disease prevention in clinical practice[J].Eur Heart J,2016,37(29):2315-2381.
[5] SEIDMAN A,HUDIS C,PIERRI M K,et al.Cardiac dysfunction inthe trastuzumab clinical trials experience[J].J Clin Oncol,2002,20(5):1215-1221.
[6] STRBA M,POPELOV O,VVROV A,et al.Oxidative stress,redox signaling,and metalchelationin anthracycline cardiotoxicity and pharmacological cardioprotection[J].Antioxid Redox Signal,2013,18(8):899-929.
[7] FULBRIGHT J M,EGAS-BEJAR D E,HUH W W,et al.Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy[J].Cancer Chemother Pharmacol,2015,76(6):1297-1307.
[8] BARRY E,ALVAREZ J A,SCULLY R E,et al.Anthracycline-induced cardiotoxicity:course,pathophysiology,prevention and management[J].Expert Opin Pharmacother,2007,8(8):1039-1058.
[9] GANAME J,CLAUS P,UYTTEBROECK A,et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients[J].J Am Soc Echocardiogr,2007,20(12):135l-1358.
[10] VAN DALEN E C,CARON H N,DICKINSON H O,et al.Cardioprotective interventions for cancer patients receiving anthracyclines[J].Cochrane Database Syst Rev,2008,16(2):CD003917.
[11] VACHHANI P,SHIN S,BARON J,et al.Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia[J].Leuk Res Rep,2017,7:36-39.
[12] JANBABAI G,NABATI M,FAGHIHINIA M,et al.Effect of enalapril on preventing anthracycline-induced cardiomyopathy[J].Cardiovasc Toxicol,2017,17(2):130-139.
[13] BOSCH X,ROVIRA M,SITGES M,et al.Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies.The OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies)[J].J Am Coll Cardiol,2013,61(23):2355-2362.
[14] CARDINALE D,COLOMBO A,LAMANTIA G,et al.Anthracycline-induced cardiomyopathy:clinical relevance and response topharmacologic therapy[J].J Am Coll Cardiol,2010,55(3):213-220.
[15] PITUSKIN E,HAYKOESKY M,MACKEY J R,et al.Rationale and design of the multidisc-iplinary approach to novel therapies in cardiology oncology research trial(MANTICORE 101-Breast):a randomized,placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI[J].BMC Cancer,2011,11:318.
[16] 刘良,刘兆喆,刘永叶,等.小剂量卡维地洛联合坎地沙坦在乳腺癌辅助化疗中预防蒽环类心脏毒性的作用[J].中华肿瘤杂志,2013,35(12):936-940.
[17] HECK S L,GULATI G,REE A H,et al.Rationaleand design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial[J].Cardiology,2012,123(4):240-247.
[18] NAKAMAE H,TSUMURA K,TERADA Y,et al.Notable effects of angiotensin II receptor blocker,valsartan,on acute cardiotoxic changes after standard chemotherapy with cyclophosph amide,doxorubicin,vincristine,and prednisolone[J].Cancer,2005,104(11):2492-2498.
[19] CADEDDU C,PIRAS A,MANTOVANI G,et al.Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation,oxidative stress,and early ventricular impairment[J].Am Heart J,2010,160(3):e481-e487.
[20] MEMORIAL SLOAN KETTERING CANCER CENTER.Carvediol for the prevention of anthracycline/anti-HER2 therapy associated cardiotoxicity among women with HER2-positive breast cancer using myocardial strain imaging for early risk stratification[EB/OL].[2017-05-30].https://clinicaltrials.gov/ct2/show/NCT02177175?term=NCT02177175&rank=1.
[21] KAYA M G,OZKAN M,GUNEBAKMAZ O,et al.Protective effects of nebivolol against anthracycline-induced cardiomyopathy:a randomized control study[J].Int J Cardiol,2013,167(5):2306-2310.
[22] 汤洁.瑞舒伐他汀对大鼠阿霉素心肌损伤的保护作用及其机制研究[D].济南:山东大学,2015.
[23] RIAD A,BIEN S,WESTERMANN D,et al.Pre-treatment with statin attenuates the cardio toxicity of doxorubicin in mice[J].Cancer Res,2009,69(2):695-699.
[24] CHOTENIMITKHUN R,D′AGOSTINO R,LAWRENCE J A,et al.Chronic statin administration may attenuate early anthracycline associated declines in left ventricular ejection function[J].Can J Cardiol,2015,31(3):302-307.
[25] AKPEK M,OZDOGRU I,SAHIN O,et al.Protective effects of spironolactone against anthracycline-induced cardiomyopathy[J].Eur J Heart Fail,2015,17(1):81-89.
[26] GREENLEE H,SHAW J,LAU Y I,et al.Effect of coenzyme Q10 on doxorubicin cytotoxicityin breast cancer cell cultures[J].Integr Cancer Ther,2012,11(3):243-250.
[27] SANTOS R V,BATISTA M L,CAPERUTO E C,et al.Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats[J].Clin Exp Pharmacol Physiol,2007,34(12):1294-1299.
[28] 蔡辉,桂金川,方向东,等.应用参芪扶正液降低蒽环类化疗药物的心脏毒性作用[J].四川医学,2015,36(11):1565-1567.
[29] 郭永强,马东红,贾国柱.生脉注射液防治阿霉素心脏毒性的临床研究[J].中西医结合心血管病电子杂志,2016,4(5):87-88.DOI:10.16282/j.cnki.cnll-9336/r.2016.05.046.
[30] 王璇.右丙亚胺联合参麦注射液对治疗急性白血病患者化疗期间心脏毒性的研究[J].中国民康医学,2015,27(12):86-88.
[31] 吕振慧,蒋树勤.右丙亚胺与参麦注射液联合治疗对减少急性白血病化疗中心脏毒性的作用[J].热带医学杂志,2017,17(5):633-636.
[32] 黄景玉,邵静.益心康泰胶囊治疗化疗所致心脏毒性临床研究[J].中医学报,2017,32(9):1597-1599.

相似文献/References:

[1]李小峰,孙新宇,张 慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
 LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(3):376.[doi:10.7683/xxyxyxb.2022.04.016]

更新日期/Last Update: 2018-03-05